Evotec and Indivumed join forces in CRC
Evotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.
Theranexus colloborates with AI expert Dyliss
Lyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntingtons Disease gene therapy in Q2/2019.
Sanofi ends option phase of rare disease partnership with Alnylam
Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.
Medigene AG in potential 1bn licence and R&D deal
Roivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation in the eastern Asian market.
AMR diagnostic specialist Gradientech raise $4.6m
Gradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST).
AgomAb Therapeutics bags 21m Series A financing
AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a 21m Series A financing.
Novartis acquires inflammasome blocker company IFM Tre
Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.
EMA recommends bluebird’s ?-thalassemia gene therapy
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
Polyneuron Pharma raise CHF22.5m in Series A financing
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.